HCV Policy & Advocacy
DDW 2015: Hepatitis C Treatment Could Yield Large Economic Benefit
- Details
- Category: HCV Policy & Advocacy
- Published on Monday, 18 May 2015 00:00
- Written by DDW
Interferon-free direct-acting antiviral therapy that cures most people with chronic hepatitis C could lead to major economic benefits by reducing lost worker productivity, according to an analysis presented at Digestive Disease Week 2015, now underway in Washington, DC.
EASL 2015: Hepatitis C Treatment May Be Highly Cost-effective for Prisoners in England
- Details
- Category: HCV Treatment
- Published on Monday, 18 May 2015 00:00
- Written by Keith Alcorn, Aidsmap
Reducing the duration of direct-acting antiviral therapy for hepatitis C will make treatment for prisoners in England highly cost-effective, and could provide an important opportunity for providing access to hepatitis C treatment for people who inject drugs, Natasha Martin from the University of California San Diego reported at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna.
3. High Hepatitis C Treatment Cost Leads to Restrictions, Sets Off Price War
- Details
- Category: Approved HCV Drugs
- Published on Monday, 12 January 2015 00:00
- Written by HIVandHepatitis.com
The high cost of new interferon-free hepatitis C treatments has raised concerns about how public payers and private insurers will be able to afford them and sparked a more general discussion about the cost of pharmaceuticals in a changing healthcare landscape.
Obama Budget Boosts U.S. HIV and Hepatitis Funding, Cuts Global AIDS and TB
- Details
- Category: HIV Policy & Advocacy
- Published on Thursday, 05 February 2015 00:00
- Written by Liz Highleyman
President Obama's proposed $4 trillion budget for fiscal year 2016 would increase funding for CDC's viral hepatitis and HIV prevention efforts, boost spending for HIV research, and allocate more to combat antibiotic resistance. The proposal would also change the law to allow Medicare to negotiate prescription drug prices, which could potentially save billions of dollars. But the plan would cut overall global health funding, including support for the Global Fund to Fight AIDS, Malaria, and Tuberculosis.
AASLD 2014: 1 Million People with Hepatitis C in the U.S. Meet High Priority Criteria for Treatment
- Details
- Category: HCV Policy & Advocacy
- Published on Wednesday, 17 December 2014 00:00
- Written by Liz Highleyman
An estimated 813,000 people with diagnosed hepatitis C in the U.S. have undergone liver disease staging and meet the "highest" or "high" priority criteria for immediate treatment, according to an analysis presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last month in Boston. The number would be even higher if taking into account undiagnosed individuals and prisoners and others excluded from household surveys.
More Articles...
- Obamacare Deadline Coming Up, Guide Offers Covered California Advice for HIV, HCV, PrEP
- Gilead Announces Generic Licensing Agreements for Hepatitis C Drug Sofosbuvir
- Community Leaders, HIV Doctors Oppose Hepatitis C Treatment Barriers
- EASL 2014: Idenix Hepatitis C Drugs Look Promising in Early Studies
Web Design and Development by